Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Monte Rosa Therapeutics Q2 EPS $(0.15) Beats $(0.39) Estimate, Sales $23.19M Beat $10.80M Estimate

Author: Benzinga Newsdesk | August 07, 2025 07:21am
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.39) by 61.14 percent. This is a 65.12 percent increase over losses of $(0.43) per share from the same period last year. The company reported quarterly sales of $23.19 million which beat the analyst consensus estimate of $10.80 million by 114.76 percent. This is a 394.01 percent increase over sales of $4.70 million the same period last year.

Posted In: GLUE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist